CN109843874B - 作为parp1、parp2和/或微管蛋白的抑制剂可用于治疗癌症的酞嗪衍生物 - Google Patents

作为parp1、parp2和/或微管蛋白的抑制剂可用于治疗癌症的酞嗪衍生物 Download PDF

Info

Publication number
CN109843874B
CN109843874B CN201780051422.3A CN201780051422A CN109843874B CN 109843874 B CN109843874 B CN 109843874B CN 201780051422 A CN201780051422 A CN 201780051422A CN 109843874 B CN109843874 B CN 109843874B
Authority
CN
China
Prior art keywords
formula
methyl
compound
unsubstituted
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780051422.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN109843874A (zh
Inventor
乔鲍·J·佩托
戴维·M·雅布隆斯
特塞·曾
哈桑·莱姆贾巴尔-阿拉维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atlasmedx Inc
University of California San Diego UCSD
Original Assignee
Atlasmedx Inc
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atlasmedx Inc, University of California San Diego UCSD filed Critical Atlasmedx Inc
Publication of CN109843874A publication Critical patent/CN109843874A/zh
Application granted granted Critical
Publication of CN109843874B publication Critical patent/CN109843874B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201780051422.3A 2016-06-24 2017-06-23 作为parp1、parp2和/或微管蛋白的抑制剂可用于治疗癌症的酞嗪衍生物 Active CN109843874B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662354449P 2016-06-24 2016-06-24
US62/354,449 2016-06-24
US201662426095P 2016-11-23 2016-11-23
US62/426,095 2016-11-23
PCT/US2017/039119 WO2017223516A1 (en) 2016-06-24 2017-06-23 Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer

Publications (2)

Publication Number Publication Date
CN109843874A CN109843874A (zh) 2019-06-04
CN109843874B true CN109843874B (zh) 2022-05-27

Family

ID=59297390

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780051422.3A Active CN109843874B (zh) 2016-06-24 2017-06-23 作为parp1、parp2和/或微管蛋白的抑制剂可用于治疗癌症的酞嗪衍生物

Country Status (15)

Country Link
US (3) US11072600B2 (https=)
EP (1) EP3475272B1 (https=)
JP (2) JP7033588B2 (https=)
KR (1) KR102494294B1 (https=)
CN (1) CN109843874B (https=)
AU (1) AU2017280334C1 (https=)
ES (1) ES2964531T3 (https=)
HU (1) HUE066216T2 (https=)
IL (1) IL263917B (https=)
MX (2) MX387726B (https=)
PL (1) PL3475272T3 (https=)
PT (1) PT3475272T (https=)
SG (1) SG11201811393WA (https=)
WO (1) WO2017223516A1 (https=)
ZA (2) ZA201808562B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10562886B2 (en) 2015-05-21 2020-02-18 The Regents Of The University Of California Anti-cancer compounds
US11028055B2 (en) 2015-11-30 2021-06-08 Children's Medical Center Corporation Compounds for treating proliferative diseases
HUE066216T2 (hu) * 2016-06-24 2024-07-28 Univ California Ftalazin származékok, mint a parp1, parp2 és/vagy tubulin inhibitorai, hasznosak a rák kezelésében
CA3095709A1 (en) 2018-04-05 2019-10-10 Noviga Research Ab Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer
CN112574122B (zh) * 2019-09-27 2024-05-31 上海天慈国际药业有限公司 一种奥拉帕尼关键中间体的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008114023A2 (en) * 2007-03-22 2008-09-25 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CN101291928A (zh) * 2005-10-19 2008-10-22 库多斯药物有限公司 4-杂芳甲基取代的酞嗪酮衍生物
CN101981013A (zh) * 2008-03-27 2011-02-23 詹森药业有限公司 作为parp和微管蛋白聚合抑制剂的四氢菲啶酮和四氢环戊二烯并喹啉酮
CN104918917A (zh) * 2012-12-31 2015-09-16 卡迪拉保健有限公司 作为聚(adp-核糖)聚合酶-1的选择性抑制剂的取代的酞嗪-1(2h)-酮衍生物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3401171A (en) 1966-03-11 1968-09-10 Smithkline Corp 2-amidobenzimidazoles
SU1019810A1 (ru) 1981-07-28 1991-04-07 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского Метиловый эфир 5(6)-[1-(2Н)-фталазинонил-4]-1Н-бензимидазолил-2-карбаминовой кислоты, обладающий антигельминтной активностью
SU1218649A1 (ru) 1984-09-19 1991-04-30 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского Способ получени метилового эфира 5(6)-[1(2Н)-фталазинонил-4-]-1Н-бензимидазолил-2-карбаминовой кислоты формулы
JP2002502844A (ja) 1998-02-03 2002-01-29 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト ５員複素環縮合ベンゾ誘導体、その調製及び医薬品としてのそれらの使用
US6677333B1 (en) 1999-01-26 2004-01-13 Ono Pharmaceutical Co., Ltd. 2H-phthalazin-1-one derivatives and drug containing its derivatives as active ingredient
DE19907813A1 (de) 1999-02-24 2000-08-31 Boehringer Ingelheim Pharma Substituierte bicyclische Heterocyclen, deren Herstellung und deren Verwendung als Arzneimittel
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
PL223343B1 (pl) 2000-10-30 2016-10-31 Kudos Pharm Ltd Zastosowanie związku, kompozycja farmaceutyczna zawierająca związek oraz pochodne ftalazynonowe
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
BRPI0408284B8 (pt) 2003-03-12 2021-05-25 Kudos Pharm Ltd compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos
JP4604086B2 (ja) 2004-05-07 2010-12-22 エグゼリクシス， インコーポレイテッド Ｒａｆモジュレーターおよびその使用方法
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
US9285378B2 (en) 2010-01-29 2016-03-15 Metanomics Gmbh Means and methods for diagnosing heart failure in a subject
CN102372706A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
EP2714703B1 (en) 2011-05-31 2021-03-10 Newgen Therapeutics, Inc. Tricyclic inhibitors of poly(adp-ribose)polymerase
KR101546743B1 (ko) * 2012-01-16 2015-08-24 한국과학기술원 인돌 유도체 화합물, 이를 포함하는 Ａｂｌ 키나제 저해제 조성물 및 이상세포 성장 질환의 예방 및 치료용 약학 조성물
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
HUE066216T2 (hu) * 2016-06-24 2024-07-28 Univ California Ftalazin származékok, mint a parp1, parp2 és/vagy tubulin inhibitorai, hasznosak a rák kezelésében

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101291928A (zh) * 2005-10-19 2008-10-22 库多斯药物有限公司 4-杂芳甲基取代的酞嗪酮衍生物
WO2008114023A2 (en) * 2007-03-22 2008-09-25 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CN101981013A (zh) * 2008-03-27 2011-02-23 詹森药业有限公司 作为parp和微管蛋白聚合抑制剂的四氢菲啶酮和四氢环戊二烯并喹啉酮
CN104918917A (zh) * 2012-12-31 2015-09-16 卡迪拉保健有限公司 作为聚(adp-核糖)聚合酶-1的选择性抑制剂的取代的酞嗪-1(2h)-酮衍生物

Also Published As

Publication number Publication date
KR20190033534A (ko) 2019-03-29
CA3029004A1 (en) 2017-12-28
US20190337928A1 (en) 2019-11-07
PT3475272T (pt) 2023-12-15
ZA202301066B (en) 2024-05-30
EP3475272B1 (en) 2023-09-13
AU2017280334A1 (en) 2019-01-17
MX2018015893A (es) 2019-08-01
US10640493B2 (en) 2020-05-05
JP7033588B2 (ja) 2022-03-10
MX2021013641A (es) 2022-01-06
US20220402894A1 (en) 2022-12-22
WO2017223516A1 (en) 2017-12-28
US11072600B2 (en) 2021-07-27
MX387726B (es) 2025-03-18
EP3475272A1 (en) 2019-05-01
AU2017280334C1 (en) 2022-10-20
JP2019522681A (ja) 2019-08-15
ZA201808562B (en) 2023-12-20
BR112018076821A2 (pt) 2019-04-02
ES2964531T3 (es) 2024-04-08
IL263917A (en) 2019-02-28
KR102494294B1 (ko) 2023-01-31
JP2022037004A (ja) 2022-03-08
HUE066216T2 (hu) 2024-07-28
US20190352283A1 (en) 2019-11-21
US12145925B2 (en) 2024-11-19
PL3475272T3 (pl) 2024-04-29
IL263917B (en) 2022-07-01
CN109843874A (zh) 2019-06-04
SG11201811393WA (en) 2019-01-30
AU2017280334B2 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
US12145925B2 (en) Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer
ES2957233T3 (es) Inhibidores de quinasa tipo receptor de activina
ES2868450T3 (es) Derivados piridicos de cetonas, método de preparación de los mismos y aplicación farmacéutica de los mismos
EP4144732A1 (en) Benzothiazolyl biaryl compound, and preparation method and use
EP3575301A1 (en) Heteroaryl[4,3-c]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof
TW201706270A (zh) 作為吲哚胺２，３-二加氧酶和／或色氨酸２，３-二加氧酶抑制劑之新穎之５或８-取代之咪唑並［１，５－ａ］吡啶
US20240190871A1 (en) Krasg12d inhibitor, preparation method therefor and application thereof
WO2016124160A1 (zh) 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用
US11708352B2 (en) Anti-cancer compounds
WO2023012153A1 (en) Valosin-containing protein (vcp/p97) inhibitors
CN110078730A (zh) 作为pi3k/mtor抑制剂的喹啉取代的稠合喹啉化合物
CN115707704B (zh) 氘代稠合三环类化合物及其组合物和用途
CN116102575B (zh) 环状2-氨基嘧啶类化合物及其用途
CA3029004C (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
HK40002445B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
HK40002445A (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
BR112018076821B1 (pt) Compostos ou sal, hidrato ou solvato dos mesmos, seus usos, formulação farmacêutica e método in vitro de inibição de parp1 e/ou parp2 e/ou tubulina
CN115368362A (zh) 作为btk抑制剂的喹喔啉酮类衍生物及其应用
EP4168413B1 (en) N-linked macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1
CN115197203A (zh) 苯胺嘧啶类化合物、其制备方法及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant